Please assess the completion status of the following clinical trial:

Trial Title: Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Majority fetal and sickle (FS or SF) hemoglobin pattern confirmed centrally by electrophoresis (screening may begin at 7 months of age)~Exclusion Criteria:~* Chronic transfusion therapy~* Cancer~* Less than 5th percentile (10th percentile for the pilot study) height, weight, or head circumference for age~* Severe developmental delay (e.g., cerebral palsy or other mental retardation, Grade III/IV intraventricular hemorrhage)~* Stroke with neurological deficit~* Surgical splenectomy~* Participating in other clinical intervention trials~* Probable or known diagnosis of Hemoglobin S-Hereditary Persistence of Fetal Hemoglobin~* Known hemoglobin S-beta plus thalassemia (hemoglobin A present)~* Any condition or chronic illness, which in the opinion of the principal investigator, makes participation unadvised or unsafe~* Inability or unwillingness to complete baseline (pre-enrollment) studies, including blood or urine specimen collection, liver-spleen scan, abdominal sonogram, neurological examination, neuropsychological testing, or transcranial Doppler ultrasound (interpretable study not required, but confirmed velocity greater than 200 cm/sec results in ineligibility)~* Previous or current treatment with hydroxyurea (HU) or another anti-sickling drug~* The following exclusion criteria are transient; patients can be re-evaluated for eligibility:~  1. Hemoglobin less than 6.0 gm/dL~ 2. Reticulocyte count less than 80,000/cu mm if hemoglobin is less than 9 gm/dL~ 3. Neutrophil count less than 2,000/cu mm~ 4. Platelet count less than 130,000/cu mm~ 5. Blood transfusion in the 2 months prior to study entry unless HbA is less than 10%~ 6. ALT greater than twice the upper limit of normal~ 7. Ferritin less than 10 ng/ml~ 8. Serum creatinine greater than twice the upper limit of normal for age~ 9. Bayley standardized mental score below 70

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 18 Months
- Healthy Volunteers: f

Study Arms:
- Hydroxyurea (Type: ACTIVE_COMPARATOR): Participants will receive hydroxyurea.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).